#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Dementia Alzheimer's type Colorectal cancer Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Hyperphagia Malignant oligodendroglioma Hydrocephalus Sjogren's syndrome Congenital cystic kidney disease B-cell small lymphocytic lymphoma refractory Paroxysmal nocturnal haemoglobinuria Pemphigoid Plasma cell myeloma Astrocytoma Sarcoma Vascular malformation Laryngeal squamous cell carcinoma Fusarium infection Propionic acidaemia More trials…

    Learn about Rare Diseases

    Sarcoma – Treatment Paraneoplastic neurological syndrome – Diagnostics Acute respiratory distress syndrome – Treatment Leiomyosarcoma – Life with Disease Medulloblastoma recurrent – Diagnostics Hepatoblastoma – Basic Information Familial amyotrophic lateral sclerosis – Basic Information Skin angiosarcoma – Trials in Disease Von Willebrand’s disease Methylmalonic acidaemia – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Olaparib Dinutuximab Beta Treprostinil Palmitil Brimonidine Tartrate Poractant Alfa Astegolimab Sar442970 Blu-263 Phosphate D5-Ethyl-Beta-D-Glucuronide Ivacaftor Salmeterol ETX-19477 Valine Mycophenolate Mofetil Stro-002 Danicamtiv Biotin SAT-3247 OXALATE Fosfomycin Trometamol Naporafenib More therapies…

    Learn about Your Condition

    Haemofiltration Diabetes insipidus Paresis Giant cell arteritis Liposarcoma recurrent Pseudoxanthoma elasticum Hysterectomy Herpes simplex meningitis Mucopolysaccharidosis II Nocturia Thrombotic microangiopathy Metabolic surgery Metastatic malignant melanoma Sickle cell anaemia Arthralgia More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

ABM

  • Long-Term Safety Study of Zigakibart in Adults with IgA Nephropathy Who Have Completed Previous Zigakibart Trials

    Recruiting

    3 1 1
    Investigated Drugs:
    • ZIGAKIBART
    Belgium Croatia Czechia France Germany Greece +2

  • Study of IncobotulinumtoxinA injections compared to placebo for prevention of episodic migraine attacks

    Recruiting

    3 1 1
    Investigated Diseases:
    • Migraine
    Investigated Drugs:
    • Clostridium Botulinum Neurotoxin Type A (150Kd), Free Of Complexing Proteins
    Austria Czechia Denmark France Germany Italy +3

  • A study to compare the effectiveness of bupivacaine hydrochloride monohydrate and lidocaine hydrochloride for treating mouth sores in patients with head and neck cancer.

    Recruiting

    3 1 1
    Investigated Drugs:
    • Lidocaine Hydrochloride
    Denmark Germany Norway Sweden

  • A study of daraxonrasib (RMC-6236) compared to observation in patients with resected pancreatic cancer following chemotherapy

    Recruiting

    3 1 1
    Investigated Diseases:
    • Ductal adenocarcinoma of pancreas
    Investigated Drugs:
    • (12M)-(1S,2S)-N-((63S,4S,Z)-11-ETHYL-12-(2-((S)-1-METHOXYETHYL)-5-(4-METHYLPIPERAZIN-1-YL)PYRIDIN-3-YL)-10,10-DIMETHYL-5,7-DIOXO-61,62,63,64,65,66-HEXAHYDRO-11H-8-OXA-2(4,2)-THIAZOLA-1(5,3)-INDOLA-6(1,3)-PYRIDAZINACYCLOUNDECAPHANE-4-YL)-2-METHYLCYCLOPROPANE-1-CARBOXAMIDE
    France Germany Italy Spain

  • A Study of Telisotuzumab Adizutecan Compared to Standard Treatment in Adults with Advanced Non-Small Cell Lung Cancer After Previous Treatment

    Recruiting

    4 1 1 1
    Investigated Drugs:
    • Osimertinib
    • Amivantamab
    • Carboplatin
    Austria Belgium France Germany Italy The Netherlands +3

  • A Study of S-337395 for Adults Not in Hospital with Respiratory Syncytial Virus Who Are at High Risk of Severe Disease

    Recruiting

    2 1
    Investigated Diseases:
    • Respiratory syncytial virus infection
    Bulgaria Poland
Previous Page
1 … 641 642 643 644 645 … 1,655
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!